Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, announces that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company, pursuant to which Xeno will acquire (the “Transaction”) all of the issued and outstanding common shares of Repare (the “Common Shares”). Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair.
Read the full article: Repare Therapeutics Enters into Definitive Agreement to Be Acquired by XenoTherapeutics, Inc. //
Source: https://www.businesswire.com/news/home/20251114715824/en/Repare-Therapeutics-Enters-into-Definitive-Agreement-to-be-Acquired-by-XenoTherapeutics-Inc.